AMITIZA® (lubiprostone) receives NICE recommendation

Sucampo Pharmaceuticals, Inc., has announced that the NICE has released a Final Appraisal Determination with guidance for the recommendation of the use of AMITIZA® (lubiprostone) in the treatment of chronic idiopathic constipation and associated symptoms in adults who have failed laxatives.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Gastroenterology amitiza chronic idiopathic constipation Inc. Latest News lubiprostone Sucampo Pharmaceuticals Source Type: news